Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Long-Acting Injectable of MK-5720 in Participants With Schizophrenia

Next Previous
Trial Profile

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Long-Acting Injectable of MK-5720 in Participants With Schizophrenia

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MK 5720 (Primary) ; MK 8189 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms MK-5720-001
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 26 Mar 2024 Status changed from recruiting to completed.
  • 21 Sep 2023 Status changed from not yet recruiting to recruiting.
  • 28 Aug 2023 MK-8189 oral tablet added as a study drug in period 1. For period 2, 2 more primary end-points added.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top